Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N2HF
|
|||
| Former ID |
DCL001032
|
|||
| Drug Name |
Vanoxerine
|
|||
| Synonyms |
Vanoxerina; Vanoxerinum; Vanoxerine [INN]; D-052; Vanoxerina [INN-Spanish]; Vanoxerinum [INN-Latin]; Piperazine, 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)-, dihydrochloride; 1-(2 (Bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine di-hcl; 1-(2-(Bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine; 1-(2-bis-[4-FLUOROPHENYL]-METHOXYETHYL)-4-(3-PHENYL-2-PROPYL)PIPERAZINE; 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cocaine addiction [ICD-11: 6C45.2; ICD-10: F14.2; ICD-9: 304.2] | Discontinued in Phase 1 | [1] | |
| Company |
National Institute on Drug Abuse
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H32F2N2O
|
|||
| Canonical SMILES |
C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2
|
|||
| InChIKey |
NAUWTFJOPJWYOT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 67469-69-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5006229, 8152197, 11111021, 11111022, 11113492, 11342171, 11362354, 11442527, 11466414, 11467534, 11486228, 11487756, 14759906, 26751714, 29222589, 47216990, 47515534, 47662513, 47885608, 47959976, 48110671, 48259460, 49698963, 49845980, 50070741, 50104404, 77174993, 85788343, 85788835, 90341225, 96099924, 103186824, 104303566, 108136182, 124749722, 124879806, 124879807, 124879808, 126407620, 128675645, 135026679, 135610891, 136367736, 137010568, 143156033, 170485711, 179150910, 198985300, 210274834, 210280466
|
|||
| ChEBI ID |
CHEBI:64089
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine transporter (DAT) | Target Info | Blocker | [1] |
| KEGG Pathway | Dopaminergic synapse | |||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Dopaminergic Neurogenesis | ||||
| Parkinsons Disease Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Neurotransmitter Clearance In The Synaptic Cleft | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.